EMA Authorised: Wayrilz (rilzabrutinib) — Sanofi B.V.

View source ↗

Summary

The EMA authorised Wayrilz (rilzabrutinib) for idiopathic thrombocytopenic purpura, designated as an orphan medicine in the EU.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Thrombocytopenic Purpura

Drugs mentioned

• WAYRILZ (RILZABRUTINIB)

Snippet

Status: Authorised. Therapeutic area: Purpura, Thrombocytopenic, Idiopathic. MAH: Sanofi B.V.. Decision date: 22/12/2025. Orphan medicine